Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20415589 | 1.00 | PTPN11 (0.73) | PTPN11KCNH2EGFR | |
| SCHEMBL25689916 | 0.85 | PTPN11 (0.54) | PTPN11KCNH2EGFR | |
| SCHEMBL29374178 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL29478950 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL30295961 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL25094875 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154462 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154418 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154556 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL19785503 | 0.84 | PTPN11 (1.00) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025217247-A1 | TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598916-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598915-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4479401-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4479398-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159087-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023159086-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| EP-3571189-B1 | PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2023018812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018809-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232331-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | PTPN11 430/4885KCNH2 3030/4885EGFR 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.